BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with genetic diseases. Its commercial product is Attruby, a next-generation oral small molecule TTR stabilizer for treating cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM). The company also markets NULIBRY (fosdenopterin) for molybdenum cofactor deficiency. Its pipeline includes low-dose infigratinib (FGFR1-3 inhibitor) in Phase 3 for achondroplasia and hypochondroplasia, encaleret for Autosomal Dominant Hypocalcemia Type 1 and chronic hypoparathyroidism, BBP-418 for LGMD2I, and BBP-812 (AAV gene therapy) for Canavan disease. BridgeBio also has programs in mendelian, oncology, and gene therapy areas.

BridgeBio Pharma is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol BBIO. Its shares trade in United States dollars (USD), which is the company's reporting currency. As a US-based company listed on a major American exchange, its stock is accessible to investors through standard brokerage accounts and is subject to US securities regulations.

BridgeBio Pharma operates in the Healthcare sector and specifically within the Biotechnology industry. This classification reflects its focus on developing innovative therapies for genetic diseases using advanced biotechnological approaches, including small molecules, enzyme replacement, and gene therapy. As a biotechnology company, it engages in research, clinical development, and commercialization of treatments that target underlying genetic causes of diseases, often addressing rare or underserved conditions.

BridgeBio Pharma is headquartered in the United States. The company's description indicates it serves patients with genetic diseases globally, though its primary market is the US, where it has commercial products like Attruby and NULIBRY. It also has license and collaboration agreements with international partners such as Bayer Consumer Care AG (Switzerland), Alexion Pharma International Operations (Ireland), Leland Stanford Junior University (US), and Novartis International Pharmaceutical Ltd. (Switzerland), suggesting a global reach in research and development.

BridgeBio Pharma generates revenue primarily through the commercialization of its approved products. Its main commercial product is Attruby, an oral TTR stabilizer for ATTR-CM, and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency. Additionally, the company may earn revenue from license and collaboration agreements, such as those with Bayer, Alexion, Stanford, and Novartis, which could include upfront payments, milestones, and royalties. Its pipeline, if approved, would add future revenue streams from products like infigratinib, encaleret, BBP-418, and BBP-812. The company also invests in research and development to expand its portfolio.